Last reviewed 2026-05-26 · How we verify

estradiol valerat

farzaneh hojjat · FDA-approved active Small molecule Under review

estradiol valerat is a Estrogen receptor agonist Small molecule drug developed by farzaneh hojjat. It is currently FDA-approved for Hormone replacement therapy for menopausal symptoms, Estrogen deficiency states.

Estradiol valerate is an estrogen receptor agonist that binds to and activates estrogen receptors to provide hormone replacement therapy.

Estradiol valerate is a small molecule that acts as an estrogen receptor alpha agonist. It is used in medical treatments for conditions such as infertility, endometrial preparation, and frozen embryo transfer, often in combination with other medications like sildenafil citrate.

At a glance

Generic name	estradiol valerat
Sponsor	farzaneh hojjat
Drug class	Estrogen receptor agonist
Target	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ)
Modality	Small molecule
Therapeutic area	Endocrinology
Phase	FDA-approved

Mechanism of action

Estradiol valerate is an esterified form of estradiol, the primary endogenous estrogen. It acts as a selective estrogen receptor agonist, binding to estrogen receptors α and β throughout the body. Upon absorption and metabolism, it releases free estradiol, which regulates gene transcription and physiological responses in estrogen-responsive tissues including the uterus, breast, bone, and cardiovascular system.

Approved indications

Hormone replacement therapy for menopausal symptoms
Estrogen deficiency states

Common side effects

Breast tenderness
Nausea
Headache
Vaginal bleeding
Fluid retention

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

estradiol valerat CI brief — competitive landscape report
estradiol valerat updates RSS · CI watch RSS
farzaneh hojjat portfolio CI

Frequently asked questions about estradiol valerat

What is estradiol valerat?

estradiol valerat is a Estrogen receptor agonist drug developed by farzaneh hojjat, indicated for Hormone replacement therapy for menopausal symptoms, Estrogen deficiency states.

How does estradiol valerat work?

Estradiol valerate is an estrogen receptor agonist that binds to and activates estrogen receptors to provide hormone replacement therapy.

What is estradiol valerat used for?

estradiol valerat is indicated for Hormone replacement therapy for menopausal symptoms, Estrogen deficiency states.

Who makes estradiol valerat?

estradiol valerat is developed and marketed by farzaneh hojjat (see full farzaneh hojjat pipeline at /company/farzaneh-hojjat).

What drug class is estradiol valerat in?

estradiol valerat belongs to the Estrogen receptor agonist class. See all Estrogen receptor agonist drugs at /class/estrogen-receptor-agonist.

What development phase is estradiol valerat in?

estradiol valerat is FDA-approved (marketed).

What are the side effects of estradiol valerat?

Common side effects of estradiol valerat include Breast tenderness, Nausea, Headache, Vaginal bleeding, Fluid retention.

What does estradiol valerat target?

estradiol valerat targets Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ) and is a Estrogen receptor agonist.

Drug class: All Estrogen receptor agonist drugs
Target: All drugs targeting Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ)
Manufacturer: farzaneh hojjat — full pipeline
Therapeutic area: All drugs in Endocrinology
Indication: Drugs for Hormone replacement therapy for menopausal symptoms
Indication: Drugs for Estrogen deficiency states

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing